A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome

作者: Friederike M.-S. Barthel , Patrick Royston , Mahesh K. B. Parmar

DOI: 10.1177/1536867X0900900401

关键词:

摘要: We present menu- and command-driven Stata programs for the calculation of sample size, number events, trial duration a novel type clinical design with time-to-event outcome two or more experimental arms. The approach is based on terminating accrual patients to inferior treatment arms at an early stage in trial, allowing through next only treatments that show predefined degree advantage against control treatment. first testing uses intermediate measure definitive (primary) rather than primary itself. are compared pairwise arm according measure. Arms survive comparison enter patient accrual, culminating comparisons features supported include unequal allocation, target hazard ratios may differ from 1 under null hypothesis, ability stop recruitment specified time after initiation. computations size power asymptotic mean variance log hazard-ratio alternative hypotheses. overall operating characteristics computed final significance levels power, correlation between hazard-ratios measures different stages. illustrate United Kingdom Medical Research Council six-arm prostate cancer which failure-free survival survival. © 2009 StataCorp LP.

参考文章(8)
Marc Buyse, Geert Molenberghs, Criteria for the validation of surrogate endpoints in randomized experiments Biometrics. ,vol. 54, pp. 1014- 1029 ,(1998) , 10.2307/2533853
M. K. B. Parmar, F. M.- S. Barthel, M. Sydes, R. Langley, R. Kaplan, E. Eisenhauer, M. Brady, N. James, M. A. Bookman, A.-M. Swart, W. Qian, P. Royston, Speeding up the Evaluation of New Agents in Cancer Journal of the National Cancer Institute. ,vol. 100, pp. 1204- 1214 ,(2008) , 10.1093/JNCI/DJN267
Patrick Royston, Mahesh K. B. Parmar, Wendi Qian, Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer Statistics in Medicine. ,vol. 22, pp. 2239- 2256 ,(2003) , 10.1002/SIM.1430
William P. McGuire, William J. Hoskins, Mark F. Brady, Paul R. Kucera, Edward E. Partridge, Katherine Y. Look, Daniel L. Clarke-Pearson, Martin Davidson, Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer The New England Journal of Medicine. ,vol. 334, pp. 1- 6 ,(1996) , 10.1056/NEJM199601043340101